TTD | Drug: D0XP4A

Drug General Information
Drug ID	D0XP4A
Former ID	DNCL002737
Drug Name	Labetuzumab I-131
Synonyms	IMMU-111
Drug Type	Antibody
Indication	Colorectal cancer [ICD9: 153, 154; ICD10:C18-C21]		Phase 2	[527751]
Company	Immunomedics
Target and Pathway
Target(s)	Carcinoembryonic antigen-related cell adhesion molecule 5	Target Info		[550467], [551006]
NetPath Pathway	TGF_beta_Receptor Signaling Pathway
References
Ref 527751	Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol.2005 Sep 20;23(27):6763-70.
Ref 550467	National Cancer Institute Drug Dictionary (drug id 692828).
Ref 551006	Clinical pipeline report, company report or official report of Immunomedics.

Drug Information